Group 1 - The company, Jiangsu Yuyue Medical Equipment Co., Ltd., will hold an online performance briefing for the 2024 fiscal year on May 9, 2025, from 15:00 to 17:00 [1] - The performance briefing aims to provide investors with a deeper understanding of the company's operational status following the release of the 2024 annual report on April 26, 2025 [1] - Key personnel attending the briefing include the Chairman/General Manager Wu Qun, Vice General Manager/CFO Zhang Yong, and independent directors [1] Group 2 - The company is soliciting questions from investors in advance of the performance briefing to enhance communication and address common concerns [2] - Investors can submit their questions until May 8, 2025, at 15:00 through a designated webpage [2] - The company encourages active participation from investors in the upcoming performance briefing [2]

Investment Rating - The report maintains a "Buy" rating for Yuyue Medical [2][10] Core Views - The company reported a better-than-expected Q1 2025 performance, with revenue of 2,436 million yuan, a year-on-year increase of 9.2%, and a net profit of 625 million yuan, a decrease of 5% [10] - The report highlights the company's product strength enhancement and accelerated overseas expansion as key growth drivers [10] - The company experienced a decline in revenue from COVID-related products in 2024, but other product lines showed growth, particularly in blood glucose management and emergency medical devices [10] Financial Data and Profit Forecast - Total revenue for 2024 is projected at 7,566 million yuan, with a year-on-year decline of 5.1%, while the forecast for 2025 is 8,730 million yuan, representing a growth of 15.4% [9][11] - The net profit for 2024 is expected to be 1,806 million yuan, down 24.6%, with a forecasted increase to 1,956 million yuan in 2025, reflecting an 8.3% growth [9][11] - The report provides a detailed breakdown of revenue growth across various product lines, indicating a strong performance in blood glucose management and emergency medical devices [10]

证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-022 出席本次年度业绩说明会的人员有：公司董事长/总经理吴群先生、公司副总 经理/首席财务官张勇先生、公司财务负责人刘丽华女士、公司独立董事钟明霞女 士、公司独立董事万遂人先生、公司董事/董事会秘书王瑞洁女士。 为充分尊重投资者、提升交流的针对性，现就公司 2024 年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2025 年 5 月 8 日（星期四）15:00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进入问题征 集专题页面。公司将在 2024 年度业绩说明会上，对投资者普遍关注的问题进行回 答。欢迎广大投资者积极参与本次业绩说明会。 （问题征集专题页面二维码） 特此公告。 江苏鱼跃医疗设备股份有限公司董事会 二〇二五年五月六日 江苏鱼跃医疗设备股份有限公司 关于举行 2024 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 江苏鱼跃医疗设备股份有限公司（以下简称"公司"）已于 2025 年 4 月 26 ...

Investment Rating - The investment rating for Yuyue Medical is "Buy" [6] Core Views - The business is gradually returning to a normalized trajectory in 2024, with short-term revenue pressure primarily due to high base effects from the previous year. Profit performance is lagging behind revenue due to fluctuations in gross margin and increased expense ratios, as well as high asset disposal gains in the previous year. Increased marketing investments are supporting market expansion for new products. The overseas localization efforts are continuously improving, with significant growth in export revenue, particularly in key products like ventilators [1][2][3]. Summary by Sections Financial Performance - In 2024, Yuyue Medical achieved operating revenue of 7.566 billion yuan, a year-on-year decline of 5.09%. The net profit attributable to the parent company was 1.806 billion yuan, down 24.63% year-on-year. The first quarter of 2025 saw operating revenue of 2.436 billion yuan, an increase of 9.17% year-on-year, while net profit decreased by 5.26% [1][2][4]. Segment Performance - The blood glucose segment led growth with revenue of 1.03 billion yuan, a year-on-year increase of 40.20%. The respiratory therapy segment reported revenue of 2.597 billion yuan, down 22.42% due to previous year's demand fluctuations, although home respiratory devices still showed growth. Clinical instruments and rehabilitation generated 2.093 billion yuan, up 0.24% [3]. Overseas Market Expansion - Export revenue reached 949 million yuan in 2024, a year-on-year increase of 30.42%. The company has over 1,000 personnel in its overseas sales team, enhancing channel expansion and localization efforts. Key products are making significant inroads in overseas markets, particularly in Southeast Asia, Europe, and South America [3]. Profit Forecast and Investment Suggestions - Revenue forecasts for 2025-2027 are 8.459 billion, 9.479 billion, and 10.611 billion yuan, with year-on-year growth rates of 11.8%, 12.1%, and 11.9% respectively. Net profit attributable to the parent company is projected to be 2.006 billion, 2.241 billion, and 2.521 billion yuan, with growth rates of 11.1%, 11.7%, and 12.5% respectively [4][5].

Group 1 - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, which has shown positive growth in recent months and has a diversified portfolio in the healthcare sector [1][3]. - As of April 30, 2025, the latest net value of the fund is 2.5180 yuan, reflecting a growth of 1.82%. The fund's return over the past month is 2.07%, ranking 41 out of 469 in its category. Over the past three months, the return is 11.71%, ranking 45 out of 467, and since the beginning of the year, the return is 10.49%, ranking 44 out of 465 [1]. - The fund's total assets amount to 2.724 billion yuan as of March 31, 2025, and it was established on November 18, 2014. The fund managers are Zhao Bei and Ding Yang [1]. Group 2 - The top ten holdings of the fund account for a total of 39.79%, with significant investments in companies such as Heng Rui Pharmaceutical (8.90%), WuXi AppTec (5.12%), and Aier Eye Hospital (4.94%) [1]. - Zhao Bei, the fund manager, has extensive experience in the healthcare sector, having been with ICBC Credit Suisse Asset Management since 2010 and managing the healthcare fund since its inception in 2014. Ding Yang, the co-manager, has a strong academic background and joined the firm in 2017 [2].

Group 1 - The core objective of the "Implementation Plan for the Digital and Intelligent Transformation of the Pharmaceutical Industry (2025-2030)" is to achieve significant progress in digital transformation by 2027, enhancing the competitiveness of the pharmaceutical industry and quality management throughout the product lifecycle [1] - The integration of new information technologies with the pharmaceutical industry is expected to drive high-quality and innovative development, with listed companies in the Shenzhen market actively participating in this transformation [1][2] - The rapid development of artificial intelligence is reshaping the pharmaceutical industry, providing unprecedented opportunities for transformation from drug development to health management [2] Group 2 - Companies are focusing on enhancing their research and development capabilities by integrating AI with medical technology, which requires overcoming various interdisciplinary barriers [2][3] - The digital transformation of the pharmaceutical industry involves automating manufacturing processes, unlocking the value of pharmaceutical data, enhancing cybersecurity, and promoting AI across the entire industry chain [3] - Capital markets play a crucial role in supporting the pharmaceutical industry through various funding channels, enabling companies to invest in high-cost areas such as innovative drug development and high-end medical device manufacturing [4][5] Group 3 - The establishment of a transparent corporate governance structure through public listing helps pharmaceutical companies improve internal decision-making processes and risk management capabilities [5] - As of April 29, 2024, 256 companies in the Shenzhen pharmaceutical and biotechnology sector reported a total revenue of 1.13 trillion yuan and a net profit of 67.63 billion yuan, with 37 companies experiencing over 50% net profit growth [5] - Companies plan to continue leveraging capital market support to drive further upgrades in the pharmaceutical industry, focusing on innovation and expanding research boundaries [6]

Investment Highlights - The report highlights the recovery of revenue growth for Yuyue Medical, with a significant increase in overseas sales, achieving a revenue of 7.57 billion yuan in 2024, down 5.1% year-on-year, and a net profit of 1.81 billion yuan, down 24.6% year-on-year [3][8] - Guotai Group's performance shows resilience in its civil explosives business, with a non-net profit growth of 17.09% year-on-year in Q1 2025, despite a slight revenue decline of 1.26% [12][13] - China Merchants Highway reported a revenue of approximately 2.803 billion yuan in Q1 2025, down 7.24% year-on-year, but net profit improved by 2.74% due to cost control and increased investment income [16][17] - Shenzhen Gas's main business in urban gas sales showed growth, with a revenue of 28.348 billion yuan in 2024, down 8.34% year-on-year, but a net profit increase of 1.19% [21][22] - New Industry's overseas business continued to grow rapidly, with a revenue of 4.535 billion yuan in 2024, up 15.41% year-on-year, and a net profit of 1.828 billion yuan, up 10.57% [25][26] - Huali Group's revenue in Q1 2025 grew by 12% year-on-year, driven by new brand collaborations and strong sales of sports shoes [30][31] - Bohai Leasing, a leading aircraft leasing company, reported a significant increase in aircraft sales revenue, reaching 12.7 billion yuan in 2024, up 61.08% year-on-year, driven by a strong aircraft market [35][36] - Weimao Electronics, an industrial intelligent connection control solution manufacturer, achieved a revenue of 260 million yuan in 2024, up 13.69% year-on-year, with a focus on expanding into emerging fields [39][40] Company-Specific Summaries Yuyue Medical (002223.SZ) - The company experienced a revenue decline in 2024 due to high base effects from the previous year, but Q1 2025 showed a recovery with a 9.2% year-on-year increase in revenue [3][9] - The product mix has led to a slight decrease in gross margin, with a 50.1% gross margin in 2024, down 1.2 percentage points year-on-year [10] - The company maintains a strong financial position with 7.08 billion yuan in cash and no short-term or long-term loans [10] Guotai Group (603977.SH) - The civil explosives business showed growth, with a revenue of 327 million yuan in Q1 2025, up 1.4% year-on-year [13][14] - The company faced a decline in electronic detonator sales but saw an increase in explosive engineering revenue [14][15] - The gross margin for Q1 2025 was 32.72%, down 0.5 percentage points year-on-year, but the non-net profit remained stable [15] China Merchants Highway (001965.SZ) - The company is actively pursuing expansion projects, including the ongoing reconstruction of key highways [17][18] - The net profit forecast for 2025-2027 is expected to grow steadily, with projected profits of 5.74 billion yuan in 2025 [18] Shenzhen Gas (601139.SH) - The urban gas sales volume increased by 2.78% in 2024, with significant growth in the Greater Bay Area [22] - The company is expected to benefit from lower upstream gas prices and increased sales volume [22][24] New Industry (300832.SZ) - The company reported a strong performance in overseas markets, with a 27.67% increase in overseas revenue [27] - The gross margin for 2024 was 72.26%, with a focus on expanding the product lineup in the chemical luminescence sector [28] Huali Group (300979.SZ) - The company maintained a strong partnership with major brands, resulting in a 12.34% revenue increase in Q1 2025 [30][31] - The company is expanding production capacity to meet growing demand, with a workforce increase of 17% [31] Bohai Leasing (000415.SZ) - The company is positioned as a global leader in aircraft leasing, with a fleet size of 1,158 aircraft [36] - The net profit forecast for 2025-2027 is expected to grow significantly, with a projected profit of 1.913 billion yuan in 2025 [37] Weimao Electronics (833346.BJ) - The company is focusing on the automotive and industrial automation sectors, with a projected growth in the vehicle wiring harness market [40][41] - The company is expanding its production capabilities to meet increasing demand in emerging markets [41]

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The company is expected to return to a stable growth trajectory with strong overseas growth [6] - The company reported a revenue of 7.57 billion yuan in 2024, a decrease of 5.1% year-on-year, and a net profit of 1.81 billion yuan, down 24.6% year-on-year [8] - The company has a strong brand presence in the domestic home medical device market and continues to expand its overseas operations, indicating significant growth potential [8] Financial Performance Summary - Revenue Forecasts: - 2023: 7,972 million yuan - 2024: 7,566 million yuan (down 5.09%) - 2025E: 8,606 million yuan (up 13.75%) - 2026E: 9,735 million yuan (up 13.11%) - 2027E: 11,037 million yuan (up 13.38%) [7] - Net Profit Forecasts: - 2023: 2,396 million yuan - 2024: 1,806 million yuan (down 24.63%) - 2025E: 2,011 million yuan (up 11.35%) - 2026E: 2,314 million yuan (up 15.07%) - 2027E: 2,661 million yuan (up 15.03%) [7] - Earnings Per Share (EPS): - 2023: 2.39 yuan - 2024: 1.80 yuan - 2025E: 2.01 yuan - 2026E: 2.31 yuan - 2027E: 2.65 yuan [7] - Return on Equity (ROE): - 2023: 20.37% - 2024: 14.40% - 2025E: 14.53% - 2026E: 15.08% - 2027E: 15.58% [7] Business Segment Performance - Respiratory therapy revenue in 2024 was 2.6 billion yuan, down 22.4% year-on-year due to high base effects from 2023 [8] - Blood glucose management and POCT revenue reached 1.03 billion yuan, up 40.2% year-on-year, with significant growth in CGM products [8] - Home health testing revenue was 1.56 billion yuan, down 0.4% year-on-year, with electronic blood pressure monitors showing double-digit growth [8] - Clinical instruments and rehabilitation revenue was 2.09 billion yuan, up 0.2% year-on-year, with good growth trends in acupuncture needles and wheelchairs [8] - Overseas revenue reached 950 million yuan, up 30.4% year-on-year, increasing its share from 9.1% to 12.5% [8] Financial Health - As of the end of Q1 2025, the company had cash and cash equivalents of 7.08 billion yuan with no short-term or long-term debt, indicating a strong financial position [8]

Core Viewpoint - The article highlights the remarkable economic and innovative achievements of Zhenjiang, a small city in Jiangsu Province, which has managed to establish itself as a hub for high-tech industries and manufacturing despite its limited size and population [3][6][13]. Group 1: Economic Performance - Zhenjiang has a GDP of 554 billion yuan in 2024, ranking 57th nationally, surpassing provincial capitals like Taiyuan and Urumqi [8]. - Despite being the smallest city in Jiangsu by area and population, Zhenjiang's GDP ranks higher than larger cities such as Huai'an and Suqian [6][8]. - The city has a high economic value relative to its size, with a focus on innovation and technology [13][24]. Group 2: Innovation and Technology - Zhenjiang ranks 77th globally in the Global Innovation Index, placing it 22nd among Chinese cities, indicating a strong innovation ecosystem [9][12]. - The city is recognized for its high innovation capacity, ranking 41st in the National Innovation City Capability Evaluation Report, which assesses 288 cities [10][12]. - Zhenjiang's high-value invention patents per ten thousand people stand at 29.71, ranking 4th in Jiangsu [24]. Group 3: Manufacturing Strength - Zhenjiang's manufacturing sector is robust, with a sales revenue of over 368.43 billion yuan in 2024, growing at 13.2%, which is above the provincial average [17][24]. - The city has established significant industrial clusters in high-end equipment manufacturing and new materials, each exceeding 100 billion yuan in scale [18][24]. - Key industries include medical devices, aerospace, and new energy equipment, with notable companies like Yiyuan Medical and Tianwei Technology leading in their respective fields [20][22]. Group 4: Strategic Development Approach - Zhenjiang has adopted a focused approach to industrial development, prioritizing sectors like artificial intelligence and low-altitude economy, avoiding over-saturation in common industries [27][29]. - The city leverages its geographical position within the Yangtze River Delta to integrate with larger cities like Shanghai and Nanjing, enhancing resource sharing and collaboration [31][32]. - Zhenjiang's development strategy emphasizes selective engagement in high-potential industries while fostering a supportive policy environment for innovation [33][34].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported better-than-expected results in Q1 2025 despite a high base effect from the previous year, with expectations for rapid growth from new products [1] - The company achieved total revenue of 7.566 billion yuan in 2024, a decrease of 5.09% year-on-year, and a net profit attributable to shareholders of 1.806 billion yuan, down 24.63% year-on-year [1] - In Q1 2025, the company reported revenue of 2.436 billion yuan, an increase of 9.17% year-on-year, and a net profit of 625 million yuan, a decrease of 5.26% year-on-year, which was better than expectations [1] Financial Performance Summary - For 2024, the company’s revenue from respiratory therapy solutions was 2.597 billion yuan, while clinical instruments and rehabilitation solutions generated 2.093 billion yuan [1] - The company’s overseas sales reached 949 million yuan in 2024, a year-on-year increase of 30.42% [1] - The gross profit margin for Q1 2025 was 50.30%, and the net profit margin was 25.58%, showing improvements compared to Q4 2024 [1] Earnings Forecast and Valuation - The forecast for net profit attributable to shareholders for 2025 and 2026 has been adjusted to 1.954 billion yuan and 2.211 billion yuan, respectively [1] - The expected price-to-earnings ratios for 2025, 2026, and 2027 are 17, 15, and 13 times, respectively [1]